LPL Financial LLC cut its stake in Semler Scientific Inc. (NASDAQ:SMLR - Free Report) by 15.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,112 shares of the company's stock after selling 17,521 shares during the period. LPL Financial LLC owned 0.97% of Semler Scientific worth $3,371,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Kovitz Investment Group Partners LLC boosted its holdings in shares of Semler Scientific by 2.2% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 22,885 shares of the company's stock worth $1,236,000 after buying an additional 501 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Semler Scientific by 318.3% during the 4th quarter. NewEdge Advisors LLC now owns 732 shares of the company's stock worth $40,000 after buying an additional 557 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Semler Scientific during the 4th quarter worth approximately $30,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Semler Scientific by 10.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,226 shares of the company's stock worth $225,000 after buying an additional 576 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its holdings in shares of Semler Scientific by 161.3% during the 1st quarter. SBI Securities Co. Ltd. now owns 959 shares of the company's stock worth $35,000 after buying an additional 592 shares in the last quarter. 49.37% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on SMLR. Benchmark began coverage on Semler Scientific in a report on Tuesday, July 8th. They issued a "buy" rating and a $101.00 target price on the stock. Maxim Group upgraded Semler Scientific to a "strong-buy" rating and set a $95.00 target price on the stock in a report on Wednesday, July 9th. Cantor Fitzgerald cut their target price on Semler Scientific from $61.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Finally, Wall Street Zen cut Semler Scientific from a "buy" rating to a "sell" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $81.75.
View Our Latest Analysis on SMLR
Semler Scientific Stock Performance
Shares of Semler Scientific stock traded down $1.11 during trading hours on Thursday, hitting $30.10. 575,280 shares of the company's stock traded hands, compared to its average volume of 581,540. Semler Scientific Inc. has a 12-month low of $21.77 and a 12-month high of $81.56. The stock has a market capitalization of $445.78 million, a price-to-earnings ratio of 12.39 and a beta of 1.34. The company has a fifty day simple moving average of $37.45 and a 200-day simple moving average of $38.07. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58.
Semler Scientific (NASDAQ:SMLR - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $5.31. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.The firm had revenue of $8.22 million during the quarter, compared to analyst estimates of $8.10 million.
Semler Scientific Company Profile
(
Free Report)
Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.
See Also
Before you consider Semler Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Semler Scientific wasn't on the list.
While Semler Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
